



個股聚焦

2024/3/26

產業類別	紡織纖維
投資建議	買進 
收盤價	目標價
NT\$ 59.80	NT\$ 66.10

本次報告：法說會

交易資料

潛在報酬率 (%)	10.54
52 週還原收盤價區間 (NT\$)	48.52-60.50
市值 (NT\$百萬元)	9020
市值 (US\$百萬美元)	283
流通在外股數 (百萬股)	151.00
董監持股 (%)	12.14
外資持股 (%)	3.99
投信持股 (%)	0.78
融資使用率 (%)	1.89

財務資料

	2023
股東權益 (NT\$百萬元)	5,599
ROA (%)	6.98
ROE (%)	10.35
淨負債比率 (%)	29.8

公司簡介

光隆為羽絨原料、服飾及寢具相關製品廠商，主要業務分為「成衣事業部」、「羽絨原料事業部」、「家居紡織事業部」及「其他」四大部門。2023 年部門別營收比重為：成衣事業部營收占 58%，羽絨原料事業部營收占 22.6%，家居紡織事業部營收占 18.7%，其他營收占 0.7%。

主要客戶：

主要競爭對手：

王章妮 channie.wang@sinopac.com

光隆 (8916 TT)

2024 年獲利可望恢復成長及高殖利率有助於評價提升

永豐觀點

雖公司 2023 年營運因客戶端去庫存而獲利衰退，然公司公告配發 3.6 元現金股利，殖利率達 6%，且因部份客戶已庫存去化完成，2Q24 本業營運可望明顯回溫，2H24 營運轉為成長，公司近六年平均現金股利配發率達 80%以上，若以 80%預估，明年現金股利可望配發 3.38 元，現金股利殖利率可望達 5.65%，有利於評價提升，研究處維持買進投資建議。

投資評價與建議


投資建議維持買進：公司 2023 年獲利雖因客戶調整庫存而獲利衰退，然 2024 年營收可望回復成長動能，且業外亦有中山區建案貢獻獲利，公司亦表示建案貢獻之獲利配發現金股利意願較高，在近期高殖利率為投資顯學之氛圍下，評價仍有提升空間，過往公司 PER 評價介於 8-16X 之間，考量今年現金股利殖利率達 6%，2025 年現金股利殖利率仍可達 5.65%，研究處給予 PER 15X 並依 2024 年稅後 EPS 估算目標價，目標價由 64.8 元上修至 66.1 元，並維持買進投資建議，潛在上漲空間 10.54%。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Mar. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Mar. 2024

營運現況與分析

光隆為羽絨原料、服飾及寢具相關製品廠商：公司成立於 1966 年，為羽絨原料加工、成衣與寢具製造廠商，公司主要業務分為「成衣事業部」、「羽絨原料事業部」、「家居紡織事業部」及「其他」四大部門。2022 年部門別營收比重為：成衣事業部營收占 55.2%，+57.2% YoY，羽絨原料事業部營收占 19.8%，+0.5% YoY，家居紡織事業部營收占 20.7%，+23.5% YoY，其他營收占 4.3%，-35.8% YoY；2023 年部門別營收比重為：成衣事業部營收占 58%，-22.2% YoY，羽絨原料事業部營收占 22.6%，-15.5% YoY，家居紡織事業部營收占 18.7%，-33.3% YoY，其他營收占 0.7%，-87.3% YoY。

圖一：公司營運據點概況



資料來源：公司法說會簡報；永豐投顧研究處整理，Mar. 2024

4Q23 稅後 EPS 為 0.07 元，低於預期：光隆 4Q23 營收 13.09 億元(-46.2% QoQ，-39.2% YoY)，其中，若依營收總額(未扣除部門間收入)估算，成衣營收占比 44.3%，-54.4% YoY，羽絨營收占比 27.8%(+28.5% YoY)，家紡營收占比 29.4%(-28.1% YoY)，4Q23 營收因成衣客戶下單趨緩而低於研究處預期，因此，毛利率 14.66% (-3.54pts. QoQ，-3.35pts. YoY)，雖毛利率因成衣營收低於預期而較研究處預估之 17.79% 低，然若排除 4Q22 基期較高因素，以 14.66% 之毛利率來看，仍較往年同期 8-12% 水準高，主要係因成衣比重逐年提高且羽絨原料事業獲利結構改善所致，營益率 2.45% (-5.97pts. QoQ，-5.58pts. YoY)，低於研究處預估之 9.16%，稅後淨利 1,460 萬元，-93.2% QoQ，-86.7% YoY，稅後 EPS 0.07 元，獲利低於預期，2023 年營收 77.08 億元(-25.2% YoY)，毛利率 17.93%，+0.82 pts. YoY，為歷年新高水準，營益率 7.75%，-1.51 pts. YoY，為歷年次高水準，稅後淨利 5.78 億元，-37.1% YoY，稅後 EPS 3.93 元，低於研究處預估之 4.62 元水準。

表一：4Q23 公司自結財報數字差異分析

百萬元	4Q23 A	4Q23 F	差異(%)	QoQ	YoY
營業收入	1,309	2,432	-46.17	-40.10	-39.15
營業毛利	192	433	-55.64	-51.76	-50.47
營業利益	32	223	-85.58	-82.55	-81.41
稅後淨利	15	130	-88.75	-93.16	-86.69
每股盈餘(元)	0.07	0.87	--	--	--
Margin (%)					
營業毛利率	14.66	17.79	--	--	--
營業利益率	2.45	9.16	--	--	--
稅後淨利率	1.12	5.34	--	--	--

資料來源：永豐投顧研究處預估及整理，Mar. 2024

表二：公司季度事業別營收及營益率趨勢

部門別	期間	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23
成衣事業	營收	1035	1145	1667	1721	1271	1041	1699	1195	580
	YoY	25.7%	75.0%	31.5%	134.2%	22.8%	-9.1%	1.9%	-30.6%	-54.4%
	營益率	9.69%	8.55%	16.41%	14.26%	8.84%	7.56%	14.01%	10.93%	-3.84%
羽絨事業	營收	549	459	663	680	278	340	528	533	357
	YoY	-1.7%	8.4%	27.0%	18.3%	-49.4%	-26.0%	-20.3%	-21.6%	28.5%
	營益率	-6.20%	1.59%	5.07%	7.43%	10.15%	3.69%	10.93%	3.63%	4.65%
家紡事業	營收	504	469	431	741	535	352	253	463	385
	YoY	-1.8%	-6.3%	-3.3%	138.3%	6.1%	-25.0%	-41.4%	-37.5%	-28.1%
	營益率	-13.16%	2.34%	4.47%	6.69%	6.59%	8.91%	1.75%	7.85%	10.37%
其他	營收	144	91	120	107	134	57	0	0	0
	YoY	349.5%	-48.8%	-33.1%	-47.1%	-7.1%	-36.8%	-99.9%	-99.9%	-99.9%
	營益率	-5.84%	-0.03%	-10.20%	4.77%	-2.23%	-0.48%	-	-	-

資料來源：永豐投顧研究處預估及整理 · Mar. 2024

2024 營運可望重回成長，現金股利殖利率亦高，具長期投資價值：展望 2024 年，公司 2023 年新增 4-5 個客戶中將有 4 個客戶持續貢獻，2023 年並再新增 2 個客戶貢獻今年營運，2023 年新客戶貢獻營收占比 6%，2024 年 6 個新客戶營收貢獻可望成長 70% 以上，其占比亦可望提升至 10% 水準，並預期成衣營收可望呈個位數成長，研究處則預估 2024 年成衣營收成長 8%，產能供應則因 2023 年底規畫之越南及印尼新產能已投入營運，印尼新廠 6 條產線已陸續投產，越南新產能則將於 4 月投入，家紡業務則因主要客戶宜得利積極拓展全球營運據點，而光隆為其客戶前十二大供應商，可望受惠客戶擴點而訂單動能增加，宜得利占公司家紡營收約 70-75%，研究處預估今年宜得利營收可望成長 20%，基此，預估家紡營收可望成長 18.8% YoY，羽絨事業則因現階段羽絨報價上漲，而公司將減少採購降低營運風險，雖公司展望營收可望持平，然研究處預估羽絨事業營收衰退 2% YoY，基此，研究處預估 2024 年營收 83.13 億元(+7.8% YoY)，雖羽絨原料成本上漲恐將影響羽絨事業毛利率下滑，然成衣營收規模增加且家紡事業宜得利客戶毛利率亦高於其他客戶所帶動，研究處預估毛利率 17.48%，-0.04 pts. YoY，並預估營益率為 8.18%，+0.43% pts. YoY，資產活化部份，台北市中山區資產活化案將於 2H24 陸續交屋貢獻獲利，若建案完銷並於今年全數交屋完畢，研究處預估將貢獻稅後 EPS 0.9 元，基此，研究處預估 2024 年稅後淨利 6.67 億元，+15.4% YoY，稅後 EPS 4.41 元，目前公司 PER 評價為 13.6X，公司過往 PER 評價區間為 8-16X，考量 2024 年公司獲利動能回復成長，且公司近六年平均現金股利配發率達 80% 以上，若以 80% 預估，明年現金股利可望配發 3.38 元，依昨日收盤價估算現金股利殖利率可望達 5.65%，評價具提升空間，基此，研究處給予 PER 15X 並依 2024 年稅後 EPS 估算目標價，目標價由 64.8 元上修至 66.1 元，並維持買進投資建議，潛在上漲空間 10.54%。

附表一：當年度損益表

單位：百萬元	24Q1F	24Q2F	24Q3F	24Q4F	2024F
營業收入	1,422	2,443	2,522	1,926	8,313
營業毛利	226	507	534	221	1,488
營業利益	82	269	301	29	680
稅前淨利	88	311	380	76	855
稅後純益	68	225	303	65	662
稅後 EPS (元)	0.45	1.52	2.01	0.43	4.41
營收 QoQ 成長率	8.63	71.80	3.23	-23.63	--
營收 YoY 成長率	-18.56	-0.97	15.42	47.14	7.85
毛利率	15.89	20.75	21.17	11.47	17.90
營益率	5.77	11.01	11.93	1.51	8.18
稅後純益率	4.78	9.21	12.01	3.37	7.96

資料來源：CMoney；永豐投顧研究處整理 · Mar. 2024

附表二：五個年度損益表

單位：百萬元	2020	2021	2022	2023	2024F
營業收入	8,499	8,061	10,304	7,708	8,313
%變動率	-16.87	-5.16	27.83	-25.19	7.85
營業毛利	1,172	989	1,763	1,382	1,488
毛利率 (%)	13.79	12.27	17.11	17.93	17.9
營業淨利	380	188	954	597	680
稅前淨利	417	611	1,131	746	855
%變動率	-31.67	46.48	85.06	-34.01	14.61
稅後純益	344	515	919	578	662
%變動率	-29.37	49.62	78.36	-37.14	14.53
稅後 EPS * (元)	2.28	3.58	6.54	3.93	4.41
市調 EPS * (元)	2.73	3.31	6.12	4.27	5.22
PER (x)	26.23	16.70	9.14	15.22	13.62
PBR (x)	1.82	1.80	1.61	1.61	1.61
每股淨值 * (元)	32.92	33.17	37.03	37.13	37.22
每股股利 (元)	3.00	3.00	3.79	3.60	--
殖利率 (%)	9.25	8.51	7.77	6.33	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理 · Mar. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

倫敦	永豐金證券(歐洲)有限公司 6 Lloyds Avenue, London EC3N 3AX, UK 電話：(44-20) 7614-9999
----	---

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤
N：Neutral 中立：未來 12 個月該股票表現將與大盤一致
S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Notice for UK Persons**

This Document may only be issued or passed on to any person in the United Kingdom if that person is of a kind described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2001 or otherwise pursuant to exemptions to section 21 of the Financial Services and Markets Act 2000. In addition, no person who is an Authorized Person may issue or pass on this document, or otherwise promote SPSE, to any person in the United Kingdom other than by the rules of the Financial Conduct Authority (FCA) applicable to such Authorized Persons. This Document is confidential and is intended solely for the use of its recipient.

Important Disclosures for U.S. Persons

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.

SinoPac Securities (Europe) Limited is regulated by the FCA